American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli(Massachusetts General Hospital), Giuseppe Giaccone(Cornell University), Timothy Aliff(Virginia Cancer Institute), Julie R. Brahmer(Johns Hopkins University), Daniel T. Milton(Virginia Cancer Institute), Joan H. Schiller(Virginia Department of Health), Thomas J. Smith(Sidney Kimmel Cancer Center), William Pao(Albany Medical Center Hospital), David Trent(Virginia Cancer Institute), Gregory A. Masters(Christiana Care Health System), John R. Strawn(American Society of Clinical Oncology), Sarah Temin(Virginia Cancer Institute), Steven Piantadosi(Brigham and Women's Hospital), Janessa L. Laskin(Virginia Cancer Institute), David H. Johnson(Boston Children's Hospital), David G. Pfister(Memorial Sloan Kettering Cancer Center), Sherman Baker(American Society of Clinical Oncology), Luke T. Nordquist(Virginia Cancer Institute)
Cited by 913
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k